Shashi Gujar

List of Publications by Year
in descending order

70 papers	5,192 citations	159585 30 h-index	114465 63 g-index
70 all docs	70 docs citations	70 times ranked	8499 citing authors

#	Article	IF	Citations
1	Metabolite profiling reveals a connection between aldehyde dehydrogenase 1A3 and GABA metabolism in breast cancer metastasis. Metabolomics, 2022, 18, 9.	3.0	10
2	Immune Checkpoint Blockade Augments Changes Within Oncolytic Virus-induced Cancer MHC-I Peptidome, Creating Novel Antitumor CD8 T Cell Reactivities. Molecular and Cellular Proteomics, 2022, 21, 100182.	3.8	3
3	Photodynamic therapy of melanoma with new, structurally similar, NIR-absorbing ruthenium (II) complexes promotes tumor growth control via distinct hallmarks of immunogenic cell death.. American Journal of Cancer Research, 2022, 12, 210-228.	1.4	0
4	IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. Heliyon, 2021, 7, e06155.	3.2	126
5	Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy. Viruses, 2021, 13, 654.	3.3	7
6	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. Journal of Experimental Medicine, 2021, 218, .	8.5	20
7	DMG26. Journal of Molecular Diagnostics, 2021, 23, 1699-1714.	2.8	1
8	Supporting the next generation of scientists to lead cancer immunology research. Cancer Immunology Research, 2021, 9, canimm.0519.2021.	3.4	1
9	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 422	9.1	1,430
10	Discovery of immunogenic cell death-inducing ruthenium-based photosensitizers for anticancer photodynamic therapy. OncoImmunology, 2021, 10, 1863626.	4.6	22
11	ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells. Cell Death and Differentiation, 2020, 27, 363-378.	11.2	82
12	Quantitative Proteome Responses to Oncolytic Reovirus in GM-CSF- and M-CSF-Differentiated Bone Marrow-Derived Cells. Journal of Proteome Research, 2020, 19, 708-718.	3.7	4
13	Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma. Trends in Cancer, 2020, 6, 9-12.	7.4	11
14	Closely related reovirus lab strains induce opposite expression of RIG-I/IFN-dependent versus -independent host genes, via mechanisms of slow replication versus polymorphisms in dsRNA binding Ïƒ3 respectively. PLoS Pathogens, 2020, 16, e1008803.	4.7	19
15	Cytokines in oncolytic virotherapy. Cytokine and Growth Factor Reviews, 2020, 56, 4-27.	7.2	33
16	Repurposing CD8 ⁺ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?. OncoImmunology, 2020, 9, 1794424.	4.6	10
17	Neuronal mitochondrial calcium uniporter deficiency exacerbates axonal injury and suppresses remyelination in mice subjected to experimental autoimmune encephalomyelitis. Experimental Neurology, 2020, 333, 113430.	4.1	5
18	Near-infrared absorbing Ru(<scp>ii</scp>) complexes act as immunoprotective photodynamic therapy (PDT) agents against aggressive melanoma. Chemical Science, 2020, 11, 11740-11762.	7.4	67

#	Article	IF	Citations
19	Targeted Metabolic Reprogramming to Improve the Efficacy of Oncolytic Virus Therapy. Molecular Therapy, 2020, 28, 1417-1421.	8.2	17
20	Improving MHC-I Ligand Identification by Incorporating Targeted Searches of Mass Spectrometry Data. Methods in Molecular Biology, 2020, 2120, 161-171.	0.9	1
21	Title is missing!. , 2020, 16, e1008803.		0
22	Title is missing!. , 2020, 16, e1008803.		0
23	Title is missing!. , 2020, 16, e1008803.		0
24	Title is missing!. , 2020, 16, e1008803.		0
25	SnapShot: Cancer Immunotherapy with Oncolytic Viruses. Cell, 2019, 176, 1240-1240.e1.	28.9	50
26	Improving MHC-I Ligand Identifications from LC-MS/MS Data by Incorporating Allelic Peptide Motifs. Proteomics, 2019, 19, 1800458.	2.2	2
27	Inhibition of Pyruvate Dehydrogenase Kinase Enhances the Antitumor Efficacy of Oncolytic Reovirus. Cancer Research, 2019, 79, 3824-3836.	0.9	21
28	Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy. Journal of Proteome Research, 2019, 18, 2666-2675.	3.7	22
29	The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways. Cell Calcium, 2019, 79, 80-88.	2.4	46
30	Regulation of the proline regulatory axis and autophagy modulates stemness in TP73/p73 deficient cancer stem-like cells. Autophagy, 2019, 15, 934-936.	9.1	16
31	TRPM2 ion channel promotes gastric cancer migration, invasion and tumor growth through the AKT signaling pathway. Scientific Reports, 2019, 9, 4182.	3.3	48
32	Multiplexed Relative Quantitation with Isobaric Tagging Mass Spectrometry Reveals Class I Major Histocompatibility Complex Ligand Dynamics in Response to Doxorubicin. Analytical Chemistry, 2019, 91, 5106-5115.	6.5	27
33	TAp73 Modifies Metabolism and Positively Regulates Growth of Cancer Stemâ€"Like Cells in a Redox-Sensitive Manner. Clinical Cancer Research, 2019, 25, 2001-2017.	7.0	25
34	HDAC6 differentially regulates autophagy in stem-like versus differentiated cancer cells. Autophagy, 2019, 15, 686-706.	9.1	32
35	Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433. Chemical Reviews, 2019, 119, 797-828.	47.7	899
36	Regulation of Cancer and Cancer-Related Genes via NAD+. Antioxidants and Redox Signaling, 2019, 30, 906-923.	5.4	24

#	Article	IF	Citations
37	TRPM2 Silencing Causes G2/M Arrest and Apoptosis in Lung Cancer Cells via Increasing Intracellular ROS and RNS Levels and Activating the JNK Pathway. Cellular Physiology and Biochemistry, 2019, 52, 742-757.	1.6	25
38	Enhancing Mass Spectrometry-Based MHC-I Peptide Identification Through a Targeted Database Search Approach. Methods in Molecular Biology, 2019, 2024, 301-307.	0.9	2
39	Heating it up: Oncolytic viruses make tumors â€˜hotâ€™ and suitable for checkpoint blockade immunotherapies. OncoImmunology, 2018, 7, e1442169.	4.6	85
40	Potentiating prostate cancer immunotherapy with oncolytic viruses. Nature Reviews Urology, 2018, 15, 235-250.	3.8	46
41	TRPM2 channelâ€“mediated regulation of autophagy maintains mitochondrial function and promotes gastric cancer cell survival via the JNK-signaling pathway. Journal of Biological Chemistry, 2018, 293, 3637-3650.	3.4	89
42	Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. Trends in Immunology, 2018, 39, 209-221.	6.8	153
43	Oncogenic RAS-induced downregulation of ATG12 is required for survival of malignant intestinal epithelial cells. Autophagy, 2018, 14, 134-151.	9.1	8
44	Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells. Cell Death and Disease, 2018, 9, 990.	6.3	22
45	The NAD+ Salvage Pathway Supports PHGDH-Driven Serine Biosynthesis. Cell Reports, 2018, 24, 2381-2391.e5.	6.4	47
46	RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers. Molecular Therapy, 2018, 26, 2019-2033.	8.2	29
47	Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy. Frontiers in Immunology, 2018, 9, 654.	4.8	42
48	Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology, 2018, 7, e1503032.	4.6	67
49	Hide-and-seek: the interplay between cancer stem cells and the immune system. Carcinogenesis, 2017, 38, 107-118.	2.8	78
50	MHC-I Ligand Discovery Using Targeted Database Searches of Mass Spectrometry Data: Implications for T-Cell Immunotherapies. Journal of Proteome Research, 2017, 16, 1806-1816.	3.7	65
51	Autophagic homeostasis is required for the pluripotency of cancer stem cells. Autophagy, 2017, 13, 264-284.	9.1	108
52	Quantitative Temporal in Vivo Proteomics Deciphers the Transition of Virus-Driven Myeloid Cells into M2 Macrophages. Journal of Proteome Research, 2017, 16, 3391-3406.	3.7	15
53	Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines. Frontiers in Immunology, 2017, 8, 800.	4.8	13
54	A Qualitative Evaluation of Program Budgeting and Marginal Analysis in a Canadian Pediatric Tertiary Care Institution. Applied Health Economics and Health Policy, 2016, 14, 559-568.	2.1	6

#	Article	IF	Citations
55	NAD+ salvage pathway in cancer metabolism and therapy. Pharmacological Research, 2016, 114, 274-283.	7.1	104
56	Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy. Viruses, 2015, 7, 6506-6525.	3.3	30
57	Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling. Molecular Oncology, 2015, 9, 17-31.	4.6	102
58	Reovirus in cancer therapy: an evidence-based review. Oncolytic Virotherapy, 2014, 3, 69.	6.0	46
59	Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. OncoImmunology, 2014, 3, e27622.	4.6	18
60	The NAD⁺synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target. Cell Cycle, 2014, 13, 1041-1048.	2.6	30
61	Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms. British Journal of Cancer, 2014, 110, 83-93.	6.4	54
62	Core Needle Biopsy of Breast Cancer Tumors Increases Distant Metastases in a Mouse Model. Neoplasia, 2014, 16, 950-960.	5.3	74
63	Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation. Frontiers in Oncology, 2014, 4, 77.	2.8	47
64	Multifaceted Therapeutic Targeting of Ovarian Peritoneal Carcinomatosis Through Virus-induced Immunomodulation. Molecular Therapy, 2013, 21, 338-347.	8.2	63
65	Activation of p53 by Chemotherapeutic Agents Enhances Reovirus Oncolysis. PLoS ONE, 2013, 8, e54006.	2.5	21
66	Aldehyde Dehydrogenase Activity of Breast Cancer Stem Cells Is Primarily Due To Isoform ALDH1A3 and Its Expression Is Predictive of Metastasis. Stem Cells, 2011, 29, 32-45.	3.2	402
67	Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer. Molecular Therapy, 2011, 19, 797-804.	8.2	71
68	Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity. Molecular Cancer Therapeutics, 2010, 9, 2924-2933.	4.1	103
69	De novo infection and propagation of wild-type Hepatitis C virus in human T lymphocytes in vitro. Journal of General Virology, 2006, 87, 3577-3586.	2.9	42
70	Flow Cytometric Quantification of T Cell Proliferation and Division Kinetics in Woodchuck Model of Hepatitis B. Immunological Investigations, 2005, 34, 215-236.	2.0	4